Date: 2015-01-12
Type of information: Nomination
Compound:
Company: CTI Biopharma - previously known as Cell Therapeutics (USA - WA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 12, 2015, CTI BioPharma announced the appointment of Alan K. Burnett, M.D., to serve as the strategic leader for myeloid development. Dr. Burnett most recently served as Professor and Head of the Department of Haematology in the Institute of Cancer and Genetics at Cardiff University and is highly regarded internationally for his work in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Dr. Burnett will be responsible for creating and implementing the strategic development program for CTI BioPharma\'s compounds in myeloid malignancies with a major focus on supplementing CTI BioPharma\'s current late-stage development programs in chronic myeloproliferative diseases and international development programs in other myeloid malignancies such as acute myeloid leukemias and myelodysplasia. Dr. Burnett will also help to identify promising earlier stage targets and therapeutics for potential development collaborations. Dr. Burnett trained at Glasgow University in the United Kindgdom (UK). He did postgraduate research in the Ben May Laboratory for Cancer Research, University of Chicago, and returned to Glasgow where he established the Stem Cell Programme, including the first autografts in AML in remission. He was appointed Chair of the Medical Research Council (MRC) Adult Leukaemia Working Party in 1989 and has acted as a coordinator of numerous MRC large hematologic cancer clinical trials. He was appointed Professor and Head of the Department of Haematology at the University of Wales College of Medicine (now Cardiff University) in 1992. In 2002, the National Cancer Research Institute was established in the UK and Dr. Burnett was appointed as Chair of the National Cancer Research Institute Haematological Oncology Study Group until 2006. Dr. Burnett has served on numerous advisory committees, and is past President of the British Society of Haematology and Chair of the UK National Training Programme. He was elected as a Fellow of the Academy of Medical Science in 2002, was awarded the Gold Medal of the British Society for Haematology in 2004 and was appointed as an MBE in the Queen\'s Birthday Honours for services to Medicine in 2008, and gave the prestigious Ham Wasserman Lecture at the American Society of Hematology meeting in 2012.
Financial terms:
Latest news:
